Multiple sclerosis (MS) is characterized by chronic inflammation ... Current treatment guidelines recommend starting disease-modifying therapies soon after disease onset. These treatments have ...

Leerink Partners analyst Faisal Khurshid reiterated a Buy rating on Immunic (IMUX – Research Report) on November 7 and set a price target ...

Opens in a new tab or window The quest to understand and slow disease progression in multiple sclerosis (MS) continued in ...

Shares of the company rose about 1% at $185.20 in premarket trading. The drugmaker has slashed jobs and pulled the plug on ...

Oct. 17, 2024 — In a study of commonly used treatments for multiple sclerosis, both medical and behavioral interventions, and a combination of the two, resulted in significant improvements in ...

Medication and cognitive behavioral therapy can both help fight MS-related fatigue. A person’s sleep habits did play a role.

Columnist Ahna Crum, a veteran of hurricanes, compares them with the struggles that are part of living with her multiple ...

The researchers observed an increase in OOP costs for multiple sclerosis medications, by an average of 217%. (HealthDay News) — Generic medications reduce the out-of-pocket (OOP) costs for ...

Smoldering-associated worsening (SAW) of multiple sclerosis (MS) deserves a broader ... authors allowed, because no licensed ...

Multiple sclerosis (MS) is a debilitating disease of the brain and spinal cord that impacts millions worldwide.

People with multiple sclerosis spent an average of $750 in out-of-pocket fees on medicines in 2012, and that amount soared to $2,378 annually in 2021, according to a new study. The study  examined the ...

A first healthy adults group has been dosed in an early clinical trial of an oral and myelin-protective treatment for all ...